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One of the major social issues nowadays is the aging
society. Korea is already an aging society, and 63 cities and
districts are ultra-aged societies where the rate of people older
than 65 yr exceeds 20%. Among them, more than 67% are
women. These statistics reveal the importance of healthcare for
older women. Disease and disability of older women are very
closely related to the loss of female sex hormones after
menopause. Major hormone-dependent aging problems in
women such as osteoporosis, Alzheimer’s disease (AD),
urinary incontinence, and coronary atherosclerosis were
surveyed in this review, and the key role of hormones in those
diseases and hormone replacement therapy (HRT) were
summarized. We expect that this review would provide some
understanding of factors that must be considered to give
optimal care to older women for healthy lives.
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INTRODUCTION
According to the report of National Statistics
Office of Korea in 2007, life expectancy of Korean
women is anticipated to extend to an average age
of 81 yr. Women’s lives are very closely related
to female sex hormones. Hormonal changes
proceed gradually in men but women encounter
fast hormonal change (menopause). Menopause,
the permanent loss of menstruation after
amenorrhea lasting more than 1 yr due to the loss
of estrogen production by the ovaries, is a major
aging process of women and most women
encounter this hormonal change between 40 and
55 yr of age.
1 Therefore, many women spend
almost 1/3 of their lives in menopause. As women
age, they are more likely to experience disease
and disability.
2
The effects of ovarian steroids are very diverse.
Although sexual dysfunction is the most well-
known disability of women after menopause,
there are many effects of female sex hormones on
other vaginal functions. They may play a role in
the pathophysiology of senescence. Whereas only
subtle changes occur in pituitary dynamic,
adrenal gland physiology, and thyroid function,
changes in glucose homeostasis, reproductive
function, and calcium metabolism are more
apparent.
3 There are significant alterations in
metabolism of skin and hair, body composition,
and subcutaneous fat distribution throughout
life.
4 Therefore, women have many diseases and
disabilities requiring intervention and treatment
after menopause.
5 However, HRT has not been
used in 2/3 of Korean postmenopausal women
with higher rates in older population.
6 When
used, it tends to be used for treatment of
menopausal symptoms.
This review explored major significant diseases
in older women that are hormone-dependent
including osteoporosis, AD, urinary incontinence,
and coronary atherosclerosis, and we would like
to provide some understanding of factors that
must be considered in order to provide optimal
care for these patients.
OSTEOPOROSIS
Osteoporosis is a worldwide problem and the
most prevalent metabolic bone disease in
developed countries including the United States.
7
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Women are generally disproportionably affected
by osteoporosis in developed countries, and
fracture rates among women are approximately
twice as high as men.
8 The cause of osteoporosis
is very complex but it is clear that hormonal
changes after menopause increase the rate of bone
resorption, leading to greater risk of osteoporosis.
9
HRT with estrogen only or estrogen and
progesterone has been used for treatment of
osteoporosis in women. HRT has been reported to
be associated with a significant decrease in
osteoporosis-related fracture.
10 In the Women's
Health Initiative (WHI) study, the short-term
administration of a continuous combined estrogen
and progestin regimen or standard dose of
conjugated estrogens confirmed fracture reduction
efficacy.
11,12 However, HRT has decreased after the
report came out that the overall health risks
exceed the benefits from use of estrogen and
progestin for an average 5.2 yr of follow up
among healthy postmenopausal US women.
13
Another choice to treat osteoporosis are selective
estrogen receptor modulators (SERMs). SERMs are
a class of medications that act on the estrogen
receptor.
14 A characteristic that distinguishes these
substances from pure receptor agonists and
antagonists is that their action is different in
various tissues, thereby granting the possibility to
selectively inhibit or stimulate estrogen-like action
in various tissues. Raloxifen is the only SERM
currently marketed for management of
osteoporosis.
15 It has been known to have agonistic
effects on bone and lipoprotein production but
antagonistic effects on breasts.
11 A new type of
SERM, lasofoxifene, is in Phase III development
for the prevention and treatment of osteoporosis
in postmenopausal women. It has remarkably
improved oral bioavailability and selectively
binds to both estrogen receptor subtypes (estrogen
receptor-alpha or -beta) with high affinity.
16,17 It
also shows favorable safety profile, and it could
be used to treat osteoporosis in the clinical field.
ALZHEIMER’S DISEASE
AD is a major health issue for women. Women
comprise 72% of the population over the age of
85 yr, and roughly half of this group has AD.
18
Not only do women constitute a grated population
of this older population but AD is expressed
earlier in women than men.
19,20 This may be
related to estrogen loss that occurs with menopause.
The brain is a target for estrogen and other
gonadal steroids. Subsets of neurons possess
intranuclear receptors for estrogen.
21 Estrogen
receptors ( and ) act as ligand-activated α β
transcription factors. The complex of estrogen and
its receptor translocates into the cell nucleus
where it regulates transcription of target genes.
Through interactions with membrane receptors,
estrogen also influences neuronal functions.
22
Estrogen has been reported to have beneficial
effects on the nervous system. It is neuro-
protective against oxidative stress, excitatory neu-
rotoxicity, and ischemia.
23,24 It can also promote
the growth of nerve processes and modulate syn-
aptic plasticity.
25,26
Other beneficial effects of estrogen include
augmentation of cerebral blood flow, enhancing
glucose transport into the brain, and reducing in
-amyloid formation. β
27-29
In spite of its beneficial roles on the neurological
system, estrogen replacement therapy (ERD) to
treat AD remains discrepant. Many researchers
reported the preventive effect of estrogen on AD
in epidemiological studies,
30-35 and early observa-
tional studies implied that women with AD
receiving HRT had milder symptoms of dementia
than women with AD not receiving HRT.
36,37
However, the results from Women's Health
Initiative Memory Study (WHIMS) show that HRT
did not reduce dementia risk. Instead, overall
rates of dementia were increased by HRT and
HRT did not improve global cognitive test score.
38
The highly consistent and apparent effect on
verbal memory in the acute period of ERT,
particularly in the early postmenopausal period,
indicates that ERT during this period may be
especially beneficial. However, long-term use of
ERT is not a replacement for healthy lifestyle, and
it is likely that women should be able to attain the
same benefits by improving their health habits.
39
URINARY INCONTINENCE
Urogenital problems in the elderly femaleHormone-Dependent Aging Problems in Women
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population are experienced by 1/3 of women
from the age of 50 yr and onward.
40
Urinary incontinence is 1 of the most significant
urinary symptoms. Depending on pathophysiologic
processes, it is further categorized into stress urinary
incontinence (SUI), urge incontinence (sensory
and motor), mixed incontinence, reflex incontinence,
overflow incontinence, anatomic incontinence
(e.g., ectopic ureter, vesicovaginal fistula), and
behavioral incontinence (e.g., immobilization).
41
The prevalence of SUI has been reported to
increase at menopause and at postmenopausal
age, and is more common in women than men,
implicating menopause.
42 The tissues originating
from the urogenital sinus were shown to be
estrogen sensitive in as early as 1931.
43 The female
lower urinary tract is though to be a target organ
for the action of the sex steroid hormones estrogen
and progesterone since estrogen receptors are
found in the urethra and lower urinary tract.
44,45
Changes in urethral cytology are observed during
the menstrual cycle and after administration of
estrogen.
46-48 Therefore, it is reasonable to postulate
that hypoestrogenism is a factor in the develop-
ment of SUI. The therapeutic effect of estrogen on
SUI remains controversial.
49,50 The combination
therapy of estrogen and phenylpropanolamine
raises intraurethral pressure and significantly
reduces urinary loss by 35% in a standardized
physical strain test.
51 Rud et al. also suggested
that estrogen increases urethral closure pressure
and improves pressure transmission to the proximal
urethra actions that promote continence.
52
However, a large placebo controlled randomized
clinical trial with 109 patients did not uncover any
benefits from estrogen therapy in women with
subjectively documented SUI.
53 Urinary concentra-
tions of endogenous steroid metabolite including
estrogen in postmenopausal patients with SUI
were not significantly different from normal
patients,
54,55 thus more precise and controlled
studies should be carried out to find out the role
of steroid hormones in the genesis and development
of SUI.
CORONARY ATHEROSCLEROSIS
The incidence of coronary heart disease (CHD)
is extremely rare in premenopausal women, even
in a high-risk population, and much lower in
premonopausal women than in men of similar
age.
56,57 However, the incidence rapidly increases
in women after menopause and loss of ovarian
function.
58 Some results show that women who
experienced early menopause have increased risk
of heart disease. Gordon et al. reported that
women experiencing natural menopause between
45 to 49 yr or a surgical menopause between 40
to 44 yr are more likely to develop CHD than
premenopausal women of the same age.
59 Another
cohort study of postmenopausal women, age 50 -
65 yr at enrollment and followed up to 10 yr,
showed that the risk of cardiovascular mortality
was higher for women with early menopause than
those with late menopause.
60 Recently, a
significant inverse relationship has been reported
between the age at menopause and both the
prevalence and extent of atherosclerosis assessed
by ultrasound in 2588 postmenopausal women.
61
Thus, it could be suggested that endogenous
estrogen in premenopausal women provides
protection against cardiovascular disease.
62
Decreased risk of cardiovascular disease has
been known for a long time as the main expected
benefit of HRT, and conjugated estrogen was 1 of
the most frequently prescribed medications in the
US.
63,64 Several studies support this expectation.
Observation studies initially suggested a protective
function of postmenopausal HRT against heart
disease with risk reduction of about 35 - 50%.
65
Adams et al. provided direct evidence for the
beneficial effects of ERT on progression of coronary
artery atherosclerosis using ovarectomized
monkeys with 30 mo of 17 -estradiol treatment. β
66
In this study, an approximate 50% reduction in
coronary artery atherosclerosis was observed
compared to the control animals. The Women's
International Study of Long-duration Oestrogen
after Menopause (WISDOM) also showed 29%
reduction of cardiovascular disease in the HRT
treated group compared with the placebo group.
67
On the other hand, controlled clinical endpoint
studies, such as Heart and Estrogen/Progestin
Replacement Study (HERS) and the recently
completed WHI trial, reported no protective
function of HRT that consisted of conjugated
equine estrogen and medroxy progesterone-acetateByung Hwa Jung, et al.
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for the primary or secondary prevention of
coronary artery disease.
68 Similar results were also
observed in the treatment with conjugated equine.
69
The study on the effect of postmenopausal HRT on
the progression of existing coronary artery
atherosclerosis as assessed by angiography showed
no differences in disease progression in all
treatment groups.
70
The risk of cardiovascular event rather increased
in women treated with HRT for many years after
menopause.
71 However, Rossouw and colleagues
suggested that the effect of HRT would be
different depending on the starting point of
treatment since they observed that women who
initiated HRT close to menopause tended to have
reduced CHD risk compared with the increase in
CHD risk among women more distant from
menopause.
72 In spite of those controversial
studies, there is an interesting report about the
long-term study of HRT: 2763 women who were
older than 65 yr of age and had pre-existing CHD
were treated with estrogen/progestin replacement
therapy with a combination of conjugated equine
estrogen and medroxyprogesterone acetate for 4.1
yr. During the first yr of the trial, there was an
increase in relative risk, mostly seen in the first 4
mo. After 2 yr of treatment, there was a tendency
toward risk reduction, and strongest reduction of
risk in the fourth yr.
73 Therefore, the effect of HRT
on CHD seems to depend on the duration and
initiation time.
74
Despite disappointing outcomes from trials to
evaluate estrogen treatment on postmenopausal
cardiovascular disease, some considerable evidences
support the beneficial effects of estrogens in
atherosclerosis in postmenopausal women. Lack
of compliance with HRT such as increased risk of
breast cancer still remains, however, future
regimens may overcome this problem.
62
OTHERS
Skin aging has been reported to be affected by
the reduction of female hormones after men-
opause.
75 Carbohydrate metabolism and adipose
tissue distribution are also regulated by female
sex hormones, and metabolic change leads to
obesity.
76,77
ADMINISTRATION ROUTE FOR HORMONE
REPLACEMENT THERAPY
HRT has been mentioned in the several hormone-
dependent women aging problems in this review.
Regardless of many controversial studies, HRT
may play a role in the prevention of these
problems. However, adverse effects such as
increased risk of cardiovascular and breast cancer
still remain. Therefore, non-oral HRT (low-dose
transdermal HRT) has been tried to reduce the
incidence of side effects.
Transdermal HRT appears as effective as oral
HRT in preventing postmenopausal osteoporosis,
78,79
and has been shown to have beneficial effects on
vascular function and coronary heart disease risk
marker.
80 It has also been reported that cardio-
vascular and invasive breast cancer risk is lower
with transdermal estradiol than with oral estrogen.
81
However, transdermal HRT also has side effects.
It may also cause more irregular and breakthrough
bleeding with sequential and continuous therapies
than its oral counterparts.
82 Therefore, careful
adjustment to individual patients and continuous
monitoring are needed to receive the benefits
from HRT.
CONCLUSION
Over their life span, women have experienced
disease and disability that are closely related to
the loss of female sex hormones. Most diseases in
older age such as adult diseases (diabetes, obesity,
and CHD), osteoporosis, urinary incontinence,
and AD are affected by female sex hormones,
suggesting hormone control or HRT in treatment
of postmenopausal women. This review is expected
to offer a wide range of healthcare options for
women who experience perimenopause and
menopause.
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